Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

CPX-351 Extends Overall Survival Over 7+3 in Older Patients With Secondary Acute Myeloid Leukemia

Wednesday, January 25th, 2017
CHICAGO--CPX-351, a liposomal formulation of cytarabine and daunorubicin, improved overall survival compared with a standard 7+3 regimen of cytarabine and daunorubicin in older patients...

Pacritinib Leads to Better Symptom Control, Improved Cytopenias in Myelofibrosis

Tuesday, January 24th, 2017
Compared with other available treatments, the JAK2 inhibitor pacritinib leads to more effective spleen volume reduction and better symptom control in patients with myelofibrosis,...

Pooled Analysis Shows Maintenance Therapy Improves Survival in Multiple Myeloma

Saturday, December 31st, 2016
Though previous studies have indicated prolonged progression-free survival (PFS) with maintenance therapy in patients with multiple myeloma (MM), experts disagree about its effect on...

Birinapant Plus Azacitidine Not Superior to Azacitidine Alone in Myelodysplastic Syndrome

Wednesday, December 14th, 2016
CHICAGO--Adding the investigational agent birinapant to azacitidine did not improve outcomes, compared with azacitidine alone, in patients with myelodysplastic syndrome (MDS), according to results...

Women With Clotting Factor Deficiencies Have Similar Excess Bleeding Risk, Regardless of Factor Levels

Sunday, October 23rd, 2016
Women who have or are carriers for factor VIII (FVIII) or factor IX (FIX) deficiency often report excessive bleeding, though it is unclear how...

Erythropoiesis-Stimulating Agents and the Risk of Thrombosis in Cancer-Associated Anemia

Friday, October 14th, 2016
CHICAGO--Patients with cancer are at risk for developing anemia. The treatment of cancer-associated anemia remains a challenge, given that the most effective therapy for...

Pacritinib for Myelofibrosis: Follow-Up from PERSIST-1

Monday, October 3rd, 2016
Results from the phase III PERSIST-1 study presented at the 2015 ASCO Meeting showed that the JAK2 inhibitor pacritinib led to more effective spleen...

Conference Coverage: Study Evaluates Safety of Cytotoxic T Lymphocytes for Rituximab-Refractory Epstein-Barr Virus

Sunday, September 25th, 2016
For patients who have undergone stem cell or organ transplantation, the drugs administered to prevent organ rejection can weaken the immune system, which can...

Conference Coverage: In Multiple Myeloma, Carfilzomib Bests Bortezomib, But Bortezomib Bests Observation

Saturday, September 17th, 2016
Two multiple myeloma (MM) studies – one in relapsed disease and the other in newly diagnosed disease after autologous stem cell transplantation (ASCT) –...

Post-Transplant Lenalidomide Maintenance Improves Overall Survival in Myeloma Patients

Thursday, August 18th, 2016
CHICAGO--Compared with placebo or no maintenance therapy, maintenance therapy with lenalidomide lengthened overall survival (OS) for patients with multiple myeloma (MM) who had undergone...

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.